Biotechnology industries
Seattle Genetics, Inc. (SGEN) has partnered with MedImmune, Inc. to develop and commercialize antibody-drug conjugate (ADC) products. Under the collaboration, MedImmune will utilize Seattle Genetics' ADC technology to target a specific tumor target and pay an upfront fee of $2.0 million. MedImmune also has the option to access
Medical equipment industry
CorMatrix Cardiovascular and Cook Biotech have partnered to facilitate the development of cutting-edge cardiovascular medical devices using proprietary biomaterials. The cross-license agreement enables the Atlanta-based tissue-engineering company to leverage Cook's expertise in manufacturing extracellular matrix (ECM) biomaterials, expanding its product pipeline to treat cardiac tissue diseases. Potential applications
Medical equipment industry
ImClone Systems Incorporated has signed significant license agreements with Genentech and Centocor, Inc., granting the rights to patents covering various aspects of antibody technology and epidermal growth factor receptor (EGFR) antibodies. These licenses relate to Erbitux, a monoclonal antibody approved for use in metastatic colorectal cancer, and IMC-11F8, an investigational
Biotechnology industries
The US market's current influenza vaccine shortage created by Chiron's manufacturing problems has led to a significant increase in funding for biotechnology companies developing new vaccines. Local player BioDiem is making inroads in the area after announcing its first milestone payment from Nobilon, a subsidiary of
Pharmaceutical industry
ID Biomedical Corporation has formed partnerships with three prominent distributors, Henry Schein, AmerisourceBergen Corporation's Specialty Group, and McKesson Corporation, to market and distribute its Fluviral influenza vaccine in the U.S. The agreements, set to begin as early as next year, are contingent upon U.S. Food and
Pharmaceutical industry
AmerisourceBergen Corporation has announced a significant agreement to distribute influenza vaccine in the United States through its ASD Healthcare unit. The 10-year deal with ID Biomedical Corporation marks a major commitment to increasing vaccine availability for hospitals and physician offices, with plans to purchase at least 12 million doses per
Biotechnology industries
V.I. Technologies, Inc. (VITX) has secured a significant influx of capital through a private placement of its common stock and warrants, totaling $20 million. The funding, led by Great Point Partners LLC, marks a major milestone for the biotechnology company, which is developing anti-infective products. The private placement is
Biological products industry
Murray, Frank & Sailer LLP has filed a class action lawsuit on behalf of all purchasers of Chiron Corporation securities during the period between July 23, 2003, and October 5, 2004. The complaint alleges that Chiron supplied approximately half of the flu vaccines administered in the United States and that
Biological products industry
Chiron Corp. has granted a nonexclusive license to InterMune, Inc. for the research, development, and commercialization of therapeutics against hepatitis C virus (HCV) drug targets, expanding the company's efforts to combat the disease. This agreement builds on Chiron's licensing policy, which aims to provide flexibility to
Biological products industry
The United States is facing a severe shortage of flu vaccines this season due to contamination problems at the Liverpool plant of Chiron, a British-based biotech company. The shortage has led to accusations by Senator John Kerry of the Bush administration playing "fast and loose" with the truth
Biological products industry
Health authorities in the United Kingdom have blocked the release of millions of doses of influenza vaccine intended for the US market due to concerns of bacterial contamination. As a result, the US Department of Health and Human Services (HHS) may not be able to salvage any of the 46-48
Pharmaceutical industry
Amgen Inc. has acquired Tularik Inc., a gene specialist, for $1.3 billion in equity, expanding its product pipeline and filling its core therapeutic concentrations in inflammation. The deal values Tularik at $25 per share, a 47% premium to its previous closing price of $17 per share. Amgen, the world&
